<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00985751</url>
  </required_header>
  <id_info>
    <org_study_id>113171</org_study_id>
    <nct_id>NCT00985751</nct_id>
  </id_info>
  <brief_title>Safety &amp; Immunogenicity of Pneumococcal Vaccine 2189242A in Children Aged 12-23 Months at the Time of First Vaccination</brief_title>
  <official_title>Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Vaccination Regimen in Children Aged 12-23 Months at the Time of First Vaccination.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study will assess the safety, reactogenicity and immunogenicity of different
      formulations of GSK Biologicals' pneumococcal vaccine 2189242A when administered alone or in
      combination with the 10-valent pneumococcal conjugate vaccine (GSK1024850A vaccine) as a
      2-dose primary vaccination course followed by a booster dose in healthy children aged 12-23
      months at the time of first vaccination. Considering that febrile reactions are frequently
      observed following pneumococcal vaccination, usually co-administered with other routine
      paediatric vaccines, the primary study objective will focus on evaluating the increase in
      grade 3 fever (i.e. rectal temperature &gt;40.0°C).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 24, 2009</start_date>
  <completion_date type="Actual">March 2, 2011</completion_date>
  <primary_completion_date type="Actual">October 12, 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Fever &gt; 40.0°C (Rectal Temperature)</measure>
    <time_frame>Within 7 days (Day 0-Day 6) following at least one dose of the primary vaccination</time_frame>
    <description>The number of subjects with rectal temperature higher (&gt;) than 40.0 degrees Celsius (°C) is reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms</measure>
    <time_frame>During the 7-day (Days 0-6) post-vaccination period following each dose (Dose 1, Dose 2 and Booster dose)</time_frame>
    <description>Solicited local symptoms assessed include pain, redness and swelling. Grade 3 pain was defined as crying when limb was moved/spontaneously painful. Grade 3 swelling/redness was defined as swelling/redness larger than (&gt;) 30 millimeters (mm). &quot;Any&quot; is defined as incidence of the specified symptom regardless of intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms</measure>
    <time_frame>During the 7-day (Days 0-6) post-vaccination period following each dose (Dose 1, Dose 2, Booster dose)</time_frame>
    <description>Solicited general symptoms assessed include drowsiness, fever (defined as rectally temperature ≥ 38.0°C), irritability, and loss of appetite. Grade 3 drowsiness = drowsiness which prevented normal everyday activities. Grade 3 fever was defined as fever (rectally temperature) above (&gt;) 40.0 degree Celsius (°C). Grade 3 irritability = crying that could not be comforted/preventing normal activity. Grade 3 loss of appetite = not eating at all. &quot;Any&quot; is defined as incidence of the specified symptom regardless of intensity or relationship to study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Unsolicited Adverse Events (AEs)</measure>
    <time_frame>During the 31-day (Days 0-30) follow-up period after each primary dose</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. &quot;Any&quot; is defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Unsolicited Adverse Events (AEs)</measure>
    <time_frame>During the 31-day (Days 0-30) follow-up period after the booster dose</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. &quot;Any&quot; is defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>During the entire study period starting at the administration of the first vaccine dose up to study end (from Day 0 up to Month 7)</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-pneumococcal dPly and PhtD Proteins Antibody Concentrations</measure>
    <time_frame>One month post-dose 2 (Month 3), prior to the booster dose (Month 6) and one month post-booster (Month 7)</time_frame>
    <description>Seropositivity status, defined as anti-pneumococcal dPly antibody concentrations ≥ 599 Luminex Units per milliliter (LU/mL) and anti-pneumococcal PhtD antibody concentrations ≥ 391 LU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-pneumococcal Serotypes and Cross-reactive Serotypes Antibody Concentrations</measure>
    <time_frame>One month post-dose 2 (Month 3), prior to the booster dose (Month 6) and one month post-booster (Month 7)</time_frame>
    <description>Seropositivity status, defined as anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F and cross-reactive serotype 6A and 19 antibody concentrations ≥ 0.05 microgram per milliliter (µg/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes and Cross-reactive Serotypes</measure>
    <time_frame>One month post-dose 2 (Month 3), prior to the booster dose (Month 6) and one month post-booster (Month 7)</time_frame>
    <description>Seropositivity status, defined as Opsonophagocytic activity against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F and cross-reactive serotypes 6A and 19A ≥ 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations to Protein D (Anti-PD)</measure>
    <time_frame>One month post-dose 2 (Month 3), prior to the booster dose (Month 6) and one month post-booster (Month 7)</time_frame>
    <description>Seropositivity status, defined as anti-PD antibody concentrations ≥ 112 Luminex Units per milliliter (LU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Anti-dPly Antibodies Inhibiting Ply Haemolysis Activity</measure>
    <time_frame>One month post-dose 2 (Month 3), prior to the booster dose (Month 6) and one month post-booster (Month 7)</time_frame>
    <description>Inhibition of haemolysis activity of pneumolysin (Ply) by anti-dPly antibodies was measured in vitro by mean of a haemolytic assay. The haemolysis activity could be followed by measuring the level of haemoglobin released. Anti-dPly titers (for inhibition of haemolytic activity) ≥ 140.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">257</enrollment>
  <condition>Infections, Streptococcal</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal vaccine GSK2189242A (formulation 1)</intervention_name>
    <description>Three doses will be administered intramuscularly, at Month 0, 2 and 6.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal vaccine GSK2189242A (formulation 2)</intervention_name>
    <description>Three doses will be administered intramuscularly, at Month 0, 2 and 6</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A (formulation 3)</intervention_name>
    <description>Three doses will be administered intramuscularly, at Month 0, 2 and 6</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A (formulation 4)</intervention_name>
    <description>Three doses will be administered intramuscularly, at Month 0, 2 and 6</description>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal vaccine GSK1024850A</intervention_name>
    <description>Three doses will be administered intramuscularly, at Month 0, 2 and 6</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that their parent(s)/Legally Acceptable
             Representative(s) (LAR) can and will comply with the requirements of the protocol

          -  Male or female between, and including, 12 and 23 months of age at the time of the
             first vaccination.

          -  Written informed consent obtained from the parents/LAR(s) of the subject.

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product other than the study vaccine(s)
             within 30 days preceding the first dose of study vaccine, or planned use during the
             study period.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             six months prior to the first vaccine dose.

          -  Planned administration/administration of a vaccine not foreseen by the study protocol
             during the study period starting from 30 days before each dose and ending 30 days
             after each dose of vaccine(s).

          -  Previous vaccination against S. pneumoniae since birth.

          -  History of any hypersensitivity reaction following any previous vaccination.

          -  Eczema and any history of allergy

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination (no laboratory testing required), including
             human immunodeficiency virus infection.

          -  A family history of congenital or hereditary immunodeficiency.

          -  Major congenital defects or any chronic illness.

          -  History of any neurologic disorders or seizures.

          -  Acute disease and/or fever at the time of enrolment.

          -  Fever is defined as temperature &gt;= 37.5°C on oral or axillary setting, or &gt;= 38.0°C on
             rectal setting.

          -  Subjects with a minor illness without fever may be enrolled at the discretion of the
             investigator.

          -  Administration of immunoglobulins and/ or any blood products within the 3 months
             preceding the first dose of study vaccine or planned use during the study period.

          -  Child in care.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>23 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chomutov</city>
        <zip>43003</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Decin</city>
        <zip>405 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nachod</city>
        <zip>547 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Odolena voda</city>
        <zip>25070</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ostrava - Poruba</city>
        <zip>70868</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pardubice</city>
        <zip>532 03</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Plzen</city>
        <zip>305 99</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Praha 4</city>
        <zip>140 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Praha 6</city>
        <zip>1600</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Znojmo</city>
        <zip>669 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2009</study_first_submitted>
  <study_first_submitted_qc>September 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2009</study_first_posted>
  <results_first_submitted>May 11, 2017</results_first_submitted>
  <results_first_submitted_qc>May 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 6, 2017</results_first_posted>
  <disposition_first_submitted>April 1, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>April 1, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 11, 2011</disposition_first_posted>
  <last_update_submitted>May 11, 2017</last_update_submitted>
  <last_update_submitted_qc>May 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunogenicity</keyword>
  <keyword>toddlers</keyword>
  <keyword>Pneumococcal vaccine</keyword>
  <keyword>Haemophilus influenzae</keyword>
  <keyword>safety</keyword>
  <keyword>Streptococcus pneumoniae</keyword>
  <keyword>Streptococcus Pneumoniae Vaccines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Streptococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>113171</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113171</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113171</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113171</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113171</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GSK 2189242A-LD Group</title>
          <description>Subjects received 2 primary vaccination doses of GSK Biologicals’ candidate pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, Low Dose (LD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
        </group>
        <group group_id="P2">
          <title>GSK 2189242A-HD Group</title>
          <description>Subjects received 2 primary vaccination doses of GSK Biologicals’ candidate pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, High Dose (HD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
        </group>
        <group group_id="P3">
          <title>Synflorix/GSK 2189242A-LD Group</title>
          <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine combined with the pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, Low Dose (LD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
        </group>
        <group group_id="P4">
          <title>Synflorix/GSK 2189242A-HD Group</title>
          <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine combined with the pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, High Dose (HD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
        </group>
        <group group_id="P5">
          <title>Synflorix Group</title>
          <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="52"/>
                <participants group_id="P4" count="51"/>
                <participants group_id="P5" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="52"/>
                <participants group_id="P4" count="51"/>
                <participants group_id="P5" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GSK 2189242A-LD Group</title>
          <description>Subjects received 2 primary vaccination doses of GSK Biologicals’ candidate pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, Low Dose (LD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
        </group>
        <group group_id="B2">
          <title>GSK 2189242A-HD Group</title>
          <description>Subjects received 2 primary vaccination doses of GSK Biologicals’ candidate pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, High Dose (HD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
        </group>
        <group group_id="B3">
          <title>Synflorix/GSK 2189242A-LD Group</title>
          <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine combined with the pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, Low Dose (LD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
        </group>
        <group group_id="B4">
          <title>Synflorix/GSK 2189242A-HD Group</title>
          <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine combined with the pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, High Dose (HD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
        </group>
        <group group_id="B5">
          <title>Synflorix Group</title>
          <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="52"/>
            <count group_id="B4" value="51"/>
            <count group_id="B5" value="51"/>
            <count group_id="B6" value="257"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17" spread="3.6"/>
                    <measurement group_id="B2" value="16.7" spread="3.81"/>
                    <measurement group_id="B3" value="17.1" spread="4.03"/>
                    <measurement group_id="B4" value="16.8" spread="3.96"/>
                    <measurement group_id="B5" value="16.3" spread="4.18"/>
                    <measurement group_id="B6" value="16.78" spread="3.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="127"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White-Caucasian/European heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="49"/>
                    <measurement group_id="B6" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White-Arabic/North African heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Fever &gt; 40.0°C (Rectal Temperature)</title>
        <description>The number of subjects with rectal temperature higher (&gt;) than 40.0 degrees Celsius (°C) is reported.</description>
        <time_frame>Within 7 days (Day 0-Day 6) following at least one dose of the primary vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O2">
            <title>Synflorix/GSK 2189242A Group</title>
            <description>This group included subjects from Synflorix/GSK 2189242A-LD and Synflorix/GSK 2189242A-HD groups for whom pooled analysis was conducted.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Fever &gt; 40.0°C (Rectal Temperature)</title>
          <description>The number of subjects with rectal temperature higher (&gt;) than 40.0 degrees Celsius (°C) is reported.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects with at least one vaccine administration documented.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fever &gt;40°C-non-inferiority:
To compare the 2 formulations of GSK Biologicals' S. pneumoniae protein containing vaccine (GSK 2189242A) combined with Synflorix™ vaccine (pooled groups) versus Synflorix™ vaccine (Synflorix/GSK 2189242A Group minus Synflorix Group) with respect to the percentage of subjects reporting fever &gt; 40.0°C (rectal temperature) within 7 days after at least 1 dose of primary vaccination.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 95% CI for the difference between groups in the percentage of subjects with rectal temperature &gt; 40.0°C within the 7-day follow-up period following primary vaccination was computed for the Synflorix/GSK 2189242A Group minus Synflorix Group. No statistically significant difference between groups in rectal temperature &gt;40.0°C would be detected if the 95% CIs included 0 and non-inferiority would</non_inferiority_desc>
            <param_type>Difference in percentage</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.1</ci_lower_limit>
            <ci_upper_limit>5.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Fever &gt; 40.0°C (Rectal Temperature)</title>
        <description>The number of subjects with rectal temperature higher (&gt;) than 40.0 degrees Celsius (°C) is reported.</description>
        <time_frame>Within 7 days (Day 0-Day 6) following at least one dose of the primary vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O2">
            <title>GSK 2189242A Group</title>
            <description>This group included subjects from GSK 2189242A-LD and GSK 2189242A-HD groups for whom pooled analysis was conducted.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Fever &gt; 40.0°C (Rectal Temperature)</title>
          <description>The number of subjects with rectal temperature higher (&gt;) than 40.0 degrees Celsius (°C) is reported.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects with at least one vaccine administration documented.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fever &gt;40°C-non-inferiority:
To compare the 2 formulations of GSK Biologicals' S. pneumoniae protein containing vaccine GSK 2189242A (pooled groups) versus Synflorix™ vaccine (GSK 2189242A Group minus Synflorix Group) with respect to the percentage of subjects reporting fever &gt; 40.0°C (rectal temperature) within 7 days after at least 1 dose of primary vaccination.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The 95% CI for the difference between groups in the percentage of subjects with rectal temperature &gt; 40.0°C within the 7-day follow-up period following primary vaccination was computed for the GSK 2189242A Group minus Synflorix Group. No statistically significant difference between groups in rectal temperature &gt;40.0°C would be detected if the 95% CIs included 0 and non-inferiority would be express</non_inferiority_desc>
            <param_type>Difference in percentage</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.1</ci_lower_limit>
            <ci_upper_limit>5.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms</title>
        <description>Solicited local symptoms assessed include pain, redness and swelling. Grade 3 pain was defined as crying when limb was moved/spontaneously painful. Grade 3 swelling/redness was defined as swelling/redness larger than (&gt;) 30 millimeters (mm). “Any” is defined as incidence of the specified symptom regardless of intensity.</description>
        <time_frame>During the 7-day (Days 0-6) post-vaccination period following each dose (Dose 1, Dose 2 and Booster dose)</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects with at least one vaccine administration documented and with the symptom sheet filled in.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK 2189242A-LD Group</title>
            <description>Subjects received 2 primary vaccination doses of GSK Biologicals’ candidate pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, Low Dose (LD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O2">
            <title>GSK 2189242A-HD Group</title>
            <description>Subjects received 2 primary vaccination doses of GSK Biologicals’ candidate pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, High Dose (HD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O3">
            <title>Synflorix/GSK 2189242A-LD Group</title>
            <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine combined with the pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, Low Dose (LD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O4">
            <title>Synflorix/GSK 2189242A-HD Group</title>
            <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine combined with the pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, High Dose (HD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O5">
            <title>Synflorix Group</title>
            <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms</title>
          <description>Solicited local symptoms assessed include pain, redness and swelling. Grade 3 pain was defined as crying when limb was moved/spontaneously painful. Grade 3 swelling/redness was defined as swelling/redness larger than (&gt;) 30 millimeters (mm). “Any” is defined as incidence of the specified symptom regardless of intensity.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects with at least one vaccine administration documented and with the symptom sheet filled in.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Pain Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain Booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain Booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness Booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness Booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling Booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling Booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms</title>
        <description>Solicited general symptoms assessed include drowsiness, fever (defined as rectally temperature ≥ 38.0°C), irritability, and loss of appetite. Grade 3 drowsiness = drowsiness which prevented normal everyday activities. Grade 3 fever was defined as fever (rectally temperature) above (&gt;) 40.0 degree Celsius (°C). Grade 3 irritability = crying that could not be comforted/preventing normal activity. Grade 3 loss of appetite = not eating at all. “Any” is defined as incidence of the specified symptom regardless of intensity or relationship to study vaccination.</description>
        <time_frame>During the 7-day (Days 0-6) post-vaccination period following each dose (Dose 1, Dose 2, Booster dose)</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects with at least one vaccine administration documented and with the symptom sheet filled in.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK 2189242A-LD Group</title>
            <description>Subjects received 2 primary vaccination doses of GSK Biologicals’ candidate pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, Low Dose (LD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O2">
            <title>GSK 2189242A-HD Group</title>
            <description>Subjects received 2 primary vaccination doses of GSK Biologicals’ candidate pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, High Dose (HD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O3">
            <title>Synflorix/GSK 2189242A-LD Group</title>
            <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine combined with the pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, Low Dose (LD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O4">
            <title>Synflorix/GSK 2189242A-HD Group</title>
            <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine combined with the pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, High Dose (HD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O5">
            <title>Synflorix Group</title>
            <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms</title>
          <description>Solicited general symptoms assessed include drowsiness, fever (defined as rectally temperature ≥ 38.0°C), irritability, and loss of appetite. Grade 3 drowsiness = drowsiness which prevented normal everyday activities. Grade 3 fever was defined as fever (rectally temperature) above (&gt;) 40.0 degree Celsius (°C). Grade 3 irritability = crying that could not be comforted/preventing normal activity. Grade 3 loss of appetite = not eating at all. “Any” is defined as incidence of the specified symptom regardless of intensity or relationship to study vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects with at least one vaccine administration documented and with the symptom sheet filled in.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Drowsiness Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Drowsiness Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Irritability Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Loss of appetite Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Loss of appetite Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Loss of appetite Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drowsiness Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Drowsiness Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Irritability Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Loss of appetite Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Loss of appetite Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Loss of appetite Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drowsiness Booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness Booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Drowsiness Booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability Booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability Booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Irritability Booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Loss of appetite Booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Loss of appetite Booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Loss of appetite Booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever Booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever Booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever Booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Unsolicited Adverse Events (AEs)</title>
        <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. “Any” is defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.</description>
        <time_frame>During the 31-day (Days 0-30) follow-up period after each primary dose</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK 2189242A-LD Group</title>
            <description>Subjects received 2 primary vaccination doses of GSK Biologicals’ candidate pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, Low Dose (LD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O2">
            <title>GSK 2189242A-HD Group</title>
            <description>Subjects received 2 primary vaccination doses of GSK Biologicals’ candidate pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, High Dose (HD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O3">
            <title>Synflorix/GSK 2189242A-LD Group</title>
            <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine combined with the pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, Low Dose (LD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O4">
            <title>Synflorix/GSK 2189242A-HD Group</title>
            <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine combined with the pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, High Dose (HD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O5">
            <title>Synflorix Group</title>
            <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Unsolicited Adverse Events (AEs)</title>
          <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. “Any” is defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects with at least one vaccine administration documented.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Unsolicited Adverse Events (AEs)</title>
        <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. “Any” is defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.</description>
        <time_frame>During the 31-day (Days 0-30) follow-up period after the booster dose</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects with at least one vaccine administration documented and with the symptom sheet filled in.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK 2189242A-LD Group</title>
            <description>Subjects received 2 primary vaccination doses of GSK Biologicals’ candidate pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, Low Dose (LD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O2">
            <title>GSK 2189242A-HD Group</title>
            <description>Subjects received 2 primary vaccination doses of GSK Biologicals’ candidate pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, High Dose (HD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O3">
            <title>Synflorix/GSK 2189242A-LD Group</title>
            <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine combined with the pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, Low Dose (LD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O4">
            <title>Synflorix/GSK 2189242A-HD Group</title>
            <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine combined with the pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, High Dose (HD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O5">
            <title>Synflorix Group</title>
            <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Unsolicited Adverse Events (AEs)</title>
          <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. “Any” is defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects with at least one vaccine administration documented and with the symptom sheet filled in.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
        <time_frame>During the entire study period starting at the administration of the first vaccine dose up to study end (from Day 0 up to Month 7)</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK 2189242A-LD Group</title>
            <description>Subjects received 2 primary vaccination doses of GSK Biologicals’ candidate pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, Low Dose (LD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O2">
            <title>GSK 2189242A-HD Group</title>
            <description>Subjects received 2 primary vaccination doses of GSK Biologicals’ candidate pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, High Dose (HD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O3">
            <title>Synflorix/GSK 2189242A-LD Group</title>
            <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine combined with the pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, Low Dose (LD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O4">
            <title>Synflorix/GSK 2189242A-HD Group</title>
            <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine combined with the pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, High Dose (HD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O5">
            <title>Synflorix Group</title>
            <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all subjects with at least one vaccine administration documented.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-pneumococcal dPly and PhtD Proteins Antibody Concentrations</title>
        <description>Seropositivity status, defined as anti-pneumococcal dPly antibody concentrations ≥ 599 Luminex Units per milliliter (LU/mL) and anti-pneumococcal PhtD antibody concentrations ≥ 391 LU/mL.</description>
        <time_frame>One month post-dose 2 (Month 3), prior to the booster dose (Month 6) and one month post-booster (Month 7)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK 2189242A-LD Group</title>
            <description>Subjects received 2 primary vaccination doses of GSK Biologicals’ candidate pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, Low Dose (LD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O2">
            <title>GSK 2189242A-HD Group</title>
            <description>Subjects received 2 primary vaccination doses of GSK Biologicals’ candidate pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, High Dose (HD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O3">
            <title>Synflorix/GSK 2189242A-LD Group</title>
            <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine combined with the pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, Low Dose (LD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O4">
            <title>Synflorix/GSK 2189242A-HD Group</title>
            <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine combined with the pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, High Dose (HD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O5">
            <title>Synflorix Group</title>
            <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-pneumococcal dPly and PhtD Proteins Antibody Concentrations</title>
          <description>Seropositivity status, defined as anti-pneumococcal dPly antibody concentrations ≥ 599 Luminex Units per milliliter (LU/mL) and anti-pneumococcal PhtD antibody concentrations ≥ 391 LU/mL.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
          <units>LU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-dPly, Post-dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135703.5" lower_limit="95376.62" upper_limit="193081.3"/>
                    <measurement group_id="O2" value="148447.5" lower_limit="101599.9" upper_limit="216896.7"/>
                    <measurement group_id="O3" value="32436.07" lower_limit="25523.77" upper_limit="41220.35"/>
                    <measurement group_id="O4" value="57149.83" lower_limit="44908.69" upper_limit="72727.64"/>
                    <measurement group_id="O5" value="3759.82" lower_limit="2376.77" upper_limit="5947.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-dPly, Pre-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100811.4" lower_limit="74005.55" upper_limit="137326.8"/>
                    <measurement group_id="O2" value="96552.52" lower_limit="73753.5" upper_limit="126399.3"/>
                    <measurement group_id="O3" value="19573.55" lower_limit="14948.37" upper_limit="25629.82"/>
                    <measurement group_id="O4" value="29592.91" lower_limit="22065.25" upper_limit="39688.66"/>
                    <measurement group_id="O5" value="4654.16" lower_limit="2879.42" upper_limit="7522.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-dPly, Post-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="224726.2" lower_limit="178187.6" upper_limit="283419.8"/>
                    <measurement group_id="O2" value="305912.3" lower_limit="248087.9" upper_limit="377214.4"/>
                    <measurement group_id="O3" value="44123.43" lower_limit="34299.98" upper_limit="56760.29"/>
                    <measurement group_id="O4" value="85805.02" lower_limit="67740.53" upper_limit="108686.8"/>
                    <measurement group_id="O5" value="4553.43" lower_limit="2878.04" upper_limit="7204.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PhtD, Post-dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30402.84" lower_limit="20723.61" upper_limit="44602.88"/>
                    <measurement group_id="O2" value="35043.91" lower_limit="24164.16" upper_limit="50822.19"/>
                    <measurement group_id="O3" value="23438.06" lower_limit="16617.86" upper_limit="33057.36"/>
                    <measurement group_id="O4" value="22141.18" lower_limit="15065.44" upper_limit="32540.15"/>
                    <measurement group_id="O5" value="3795.68" lower_limit="2268.23" upper_limit="6351.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PhtD, Pre-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24350.58" lower_limit="17056.09" upper_limit="34764.74"/>
                    <measurement group_id="O2" value="23918.77" lower_limit="17724.59" upper_limit="32277.63"/>
                    <measurement group_id="O3" value="14375.59" lower_limit="9338.31" upper_limit="22130.1"/>
                    <measurement group_id="O4" value="12721.01" lower_limit="8498" upper_limit="19042.62"/>
                    <measurement group_id="O5" value="4814.97" lower_limit="2881.25" upper_limit="8046.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PhtD, Post-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65584.24" lower_limit="50985.27" upper_limit="84363.43"/>
                    <measurement group_id="O2" value="77312.07" lower_limit="58589.49" upper_limit="102017.6"/>
                    <measurement group_id="O3" value="32609.19" lower_limit="23615.58" upper_limit="45027.88"/>
                    <measurement group_id="O4" value="36098.18" lower_limit="26620.97" upper_limit="48949.34"/>
                    <measurement group_id="O5" value="5072.43" lower_limit="3023.97" upper_limit="8508.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-pneumococcal Serotypes and Cross-reactive Serotypes Antibody Concentrations</title>
        <description>Seropositivity status, defined as anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F and cross-reactive serotype 6A and 19 antibody concentrations ≥ 0.05 microgram per milliliter (µg/mL).</description>
        <time_frame>One month post-dose 2 (Month 3), prior to the booster dose (Month 6) and one month post-booster (Month 7)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK 2189242A-LD Group</title>
            <description>Subjects received 2 primary vaccination doses of GSK Biologicals’ candidate pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, Low Dose (LD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O2">
            <title>GSK 2189242A-HD Group</title>
            <description>Subjects received 2 primary vaccination doses of GSK Biologicals’ candidate pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, High Dose (HD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O3">
            <title>Synflorix/GSK 2189242A-LD Group</title>
            <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine combined with the pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, Low Dose (LD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O4">
            <title>Synflorix/GSK 2189242A-HD Group</title>
            <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine combined with the pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, High Dose (HD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O5">
            <title>Synflorix Group</title>
            <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-pneumococcal Serotypes and Cross-reactive Serotypes Antibody Concentrations</title>
          <description>Seropositivity status, defined as anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F and cross-reactive serotype 6A and 19 antibody concentrations ≥ 0.05 microgram per milliliter (µg/mL).</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-1, Post-Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="0.03" upper_limit="0.05"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.04" upper_limit="0.06"/>
                    <measurement group_id="O3" value="2.5" lower_limit="2.01" upper_limit="3.11"/>
                    <measurement group_id="O4" value="2.08" lower_limit="1.56" upper_limit="2.77"/>
                    <measurement group_id="O5" value="2.13" lower_limit="1.62" upper_limit="2.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-1, Pre-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="0.03" upper_limit="0.06"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.04" upper_limit="0.07"/>
                    <measurement group_id="O3" value="0.87" lower_limit="0.68" upper_limit="1.12"/>
                    <measurement group_id="O4" value="0.75" lower_limit="0.57" upper_limit="0.99"/>
                    <measurement group_id="O5" value="0.73" lower_limit="0.55" upper_limit="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-1, Post-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="0.03" upper_limit="0.06"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.04" upper_limit="0.08"/>
                    <measurement group_id="O3" value="2.69" lower_limit="2.13" upper_limit="3.39"/>
                    <measurement group_id="O4" value="2.47" lower_limit="2.03" upper_limit="3"/>
                    <measurement group_id="O5" value="2.4" lower_limit="1.85" upper_limit="3.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-4, Post-Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="0.03" upper_limit="0.08"/>
                    <measurement group_id="O2" value="0.03" lower_limit="0.02" upper_limit="0.03"/>
                    <measurement group_id="O3" value="6.42" lower_limit="5.23" upper_limit="7.87"/>
                    <measurement group_id="O4" value="6.6" lower_limit="5.12" upper_limit="8.52"/>
                    <measurement group_id="O5" value="5.67" lower_limit="4.56" upper_limit="7.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-4, Pre-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="0.03" upper_limit="0.07"/>
                    <measurement group_id="O2" value="0.03" lower_limit="0.03" upper_limit="0.03"/>
                    <measurement group_id="O3" value="2.3" lower_limit="1.82" upper_limit="2.91"/>
                    <measurement group_id="O4" value="2.36" lower_limit="1.79" upper_limit="3.11"/>
                    <measurement group_id="O5" value="2.11" lower_limit="1.68" upper_limit="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-4, Post-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="0.03" upper_limit="0.07"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.03" upper_limit="0.05"/>
                    <measurement group_id="O3" value="5.26" lower_limit="4.14" upper_limit="6.69"/>
                    <measurement group_id="O4" value="5.61" lower_limit="4.46" upper_limit="7.07"/>
                    <measurement group_id="O5" value="5.18" lower_limit="4.05" upper_limit="6.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-5, Post-Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" lower_limit="0.04" upper_limit="0.08"/>
                    <measurement group_id="O2" value="0.06" lower_limit="0.05" upper_limit="0.08"/>
                    <measurement group_id="O3" value="2.42" lower_limit="1.85" upper_limit="3.17"/>
                    <measurement group_id="O4" value="2.41" lower_limit="1.85" upper_limit="3.13"/>
                    <measurement group_id="O5" value="2.36" lower_limit="1.88" upper_limit="2.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-5, Pre-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" lower_limit="0.05" upper_limit="0.1"/>
                    <measurement group_id="O2" value="0.06" lower_limit="0.05" upper_limit="0.08"/>
                    <measurement group_id="O3" value="1.08" lower_limit="0.83" upper_limit="1.41"/>
                    <measurement group_id="O4" value="1.05" lower_limit="0.81" upper_limit="1.36"/>
                    <measurement group_id="O5" value="1.18" lower_limit="0.94" upper_limit="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-5, Post-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" lower_limit="0.05" upper_limit="0.09"/>
                    <measurement group_id="O2" value="0.07" lower_limit="0.05" upper_limit="0.09"/>
                    <measurement group_id="O3" value="3.57" lower_limit="2.79" upper_limit="4.57"/>
                    <measurement group_id="O4" value="3.45" lower_limit="2.7" upper_limit="4.41"/>
                    <measurement group_id="O5" value="3.84" lower_limit="2.98" upper_limit="4.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B, Post-Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="0.03" upper_limit="0.05"/>
                    <measurement group_id="O2" value="0.03" lower_limit="0.02" upper_limit="0.03"/>
                    <measurement group_id="O3" value="0.55" lower_limit="0.37" upper_limit="0.81"/>
                    <measurement group_id="O4" value="0.48" lower_limit="0.32" upper_limit="0.72"/>
                    <measurement group_id="O5" value="0.55" lower_limit="0.39" upper_limit="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B, Pre-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="0.03" upper_limit="0.05"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.03" upper_limit="0.05"/>
                    <measurement group_id="O3" value="0.39" lower_limit="0.28" upper_limit="0.54"/>
                    <measurement group_id="O4" value="0.42" lower_limit="0.3" upper_limit="0.59"/>
                    <measurement group_id="O5" value="0.46" lower_limit="0.34" upper_limit="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B, Post-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="0.03" upper_limit="0.06"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.03" upper_limit="0.06"/>
                    <measurement group_id="O3" value="1.08" lower_limit="0.74" upper_limit="1.57"/>
                    <measurement group_id="O4" value="1.14" lower_limit="0.83" upper_limit="1.57"/>
                    <measurement group_id="O5" value="1.08" lower_limit="0.78" upper_limit="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-7F, Post-Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="0.03" upper_limit="0.06"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.03" upper_limit="0.04"/>
                    <measurement group_id="O3" value="5.03" lower_limit="4.16" upper_limit="6.09"/>
                    <measurement group_id="O4" value="4.73" lower_limit="3.89" upper_limit="5.74"/>
                    <measurement group_id="O5" value="3.72" lower_limit="3.17" upper_limit="4.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-7F, Pre-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="0.03" upper_limit="0.06"/>
                    <measurement group_id="O2" value="0.03" lower_limit="0.03" upper_limit="0.04"/>
                    <measurement group_id="O3" value="2.6" lower_limit="2.14" upper_limit="3.15"/>
                    <measurement group_id="O4" value="2.36" lower_limit="1.94" upper_limit="2.86"/>
                    <measurement group_id="O5" value="2.14" lower_limit="1.82" upper_limit="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-7F, Post-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="0.03" upper_limit="0.06"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.03" upper_limit="0.05"/>
                    <measurement group_id="O3" value="5.9" lower_limit="4.83" upper_limit="7.2"/>
                    <measurement group_id="O4" value="5.25" lower_limit="4.36" upper_limit="6.32"/>
                    <measurement group_id="O5" value="4.65" lower_limit="3.77" upper_limit="5.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V, Post-Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="0.03" upper_limit="0.06"/>
                    <measurement group_id="O2" value="0.03" lower_limit="0.02" upper_limit="0.03"/>
                    <measurement group_id="O3" value="2.81" lower_limit="2.24" upper_limit="3.51"/>
                    <measurement group_id="O4" value="2.49" lower_limit="1.95" upper_limit="3.19"/>
                    <measurement group_id="O5" value="1.55" lower_limit="1.21" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V, Pre-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="0.03" upper_limit="0.05"/>
                    <measurement group_id="O2" value="0.03" lower_limit="0.03" upper_limit="0.04"/>
                    <measurement group_id="O3" value="1.44" lower_limit="1.15" upper_limit="1.81"/>
                    <measurement group_id="O4" value="1.26" lower_limit="0.94" upper_limit="1.67"/>
                    <measurement group_id="O5" value="0.95" lower_limit="0.73" upper_limit="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V, Post-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="0.03" upper_limit="0.06"/>
                    <measurement group_id="O2" value="0.03" lower_limit="0.02" upper_limit="0.04"/>
                    <measurement group_id="O3" value="3.13" lower_limit="2.48" upper_limit="3.93"/>
                    <measurement group_id="O4" value="3.21" lower_limit="2.45" upper_limit="4.19"/>
                    <measurement group_id="O5" value="2.18" lower_limit="1.71" upper_limit="2.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14, Post-Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0.07" upper_limit="0.14"/>
                    <measurement group_id="O2" value="0.09" lower_limit="0.06" upper_limit="0.14"/>
                    <measurement group_id="O3" value="5.18" lower_limit="3.91" upper_limit="6.86"/>
                    <measurement group_id="O4" value="3.78" lower_limit="2.92" upper_limit="4.91"/>
                    <measurement group_id="O5" value="4.63" lower_limit="3.71" upper_limit="5.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14, Pre-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" lower_limit="0.08" upper_limit="0.17"/>
                    <measurement group_id="O2" value="0.11" lower_limit="0.07" upper_limit="0.18"/>
                    <measurement group_id="O3" value="2.86" lower_limit="2.25" upper_limit="3.65"/>
                    <measurement group_id="O4" value="2.3" lower_limit="1.81" upper_limit="2.91"/>
                    <measurement group_id="O5" value="2.71" lower_limit="2.17" upper_limit="3.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14, Post-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" lower_limit="0.09" upper_limit="0.18"/>
                    <measurement group_id="O2" value="0.16" lower_limit="0.1" upper_limit="0.26"/>
                    <measurement group_id="O3" value="7.74" lower_limit="6.03" upper_limit="9.94"/>
                    <measurement group_id="O4" value="6.62" lower_limit="5.22" upper_limit="8.4"/>
                    <measurement group_id="O5" value="5.98" lower_limit="4.68" upper_limit="7.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C, Post-Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="0.03" upper_limit="0.06"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.03" upper_limit="0.05"/>
                    <measurement group_id="O3" value="13.92" lower_limit="10.75" upper_limit="18.03"/>
                    <measurement group_id="O4" value="16.92" lower_limit="13.61" upper_limit="21.03"/>
                    <measurement group_id="O5" value="12.56" lower_limit="9.8" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C, Pre-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="0.03" upper_limit="0.07"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.03" upper_limit="0.05"/>
                    <measurement group_id="O3" value="4.94" lower_limit="3.83" upper_limit="6.38"/>
                    <measurement group_id="O4" value="5.51" lower_limit="4.3" upper_limit="7.05"/>
                    <measurement group_id="O5" value="4.79" lower_limit="3.69" upper_limit="6.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C, Post-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="0.03" upper_limit="0.07"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.03" upper_limit="0.07"/>
                    <measurement group_id="O3" value="16.12" lower_limit="12.2" upper_limit="21.32"/>
                    <measurement group_id="O4" value="21.98" lower_limit="16.67" upper_limit="28.99"/>
                    <measurement group_id="O5" value="14.62" lower_limit="10.9" upper_limit="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F, Post-Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="0.03" upper_limit="0.08"/>
                    <measurement group_id="O2" value="0.06" lower_limit="0.03" upper_limit="0.12"/>
                    <measurement group_id="O3" value="8.6" lower_limit="6.37" upper_limit="11.63"/>
                    <measurement group_id="O4" value="10.08" lower_limit="7.21" upper_limit="14.09"/>
                    <measurement group_id="O5" value="8.87" lower_limit="6.2" upper_limit="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F, Pre-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" lower_limit="0.04" upper_limit="0.1"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.03" upper_limit="0.09"/>
                    <measurement group_id="O3" value="4.15" lower_limit="2.94" upper_limit="5.85"/>
                    <measurement group_id="O4" value="4.72" lower_limit="3.54" upper_limit="6.3"/>
                    <measurement group_id="O5" value="4.33" lower_limit="3.06" upper_limit="6.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F, Post-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" lower_limit="0.04" upper_limit="0.09"/>
                    <measurement group_id="O2" value="0.07" lower_limit="0.04" upper_limit="0.13"/>
                    <measurement group_id="O3" value="10.46" lower_limit="7.35" upper_limit="14.88"/>
                    <measurement group_id="O4" value="14.38" lower_limit="10.53" upper_limit="19.63"/>
                    <measurement group_id="O5" value="11.32" lower_limit="7.94" upper_limit="16.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F, Post-Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" lower_limit="0.03" upper_limit="0.04"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.03" upper_limit="0.05"/>
                    <measurement group_id="O3" value="1.19" lower_limit="0.82" upper_limit="1.74"/>
                    <measurement group_id="O4" value="0.91" lower_limit="0.62" upper_limit="1.33"/>
                    <measurement group_id="O5" value="0.73" lower_limit="0.54" upper_limit="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F, Pre-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" lower_limit="0.03" upper_limit="0.04"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.03" upper_limit="0.06"/>
                    <measurement group_id="O3" value="0.71" lower_limit="0.5" upper_limit="0.99"/>
                    <measurement group_id="O4" value="0.62" lower_limit="0.45" upper_limit="0.85"/>
                    <measurement group_id="O5" value="0.51" lower_limit="0.39" upper_limit="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F, Post-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" lower_limit="0.03" upper_limit="0.04"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.03" upper_limit="0.06"/>
                    <measurement group_id="O3" value="1.92" lower_limit="1.42" upper_limit="2.6"/>
                    <measurement group_id="O4" value="2.04" lower_limit="1.56" upper_limit="2.65"/>
                    <measurement group_id="O5" value="1.47" lower_limit="1.04" upper_limit="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6A, Post-Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="0.03" upper_limit="0.07"/>
                    <measurement group_id="O2" value="0.03" lower_limit="0.03" upper_limit="0.04"/>
                    <measurement group_id="O3" value="0.32" lower_limit="0.2" upper_limit="0.51"/>
                    <measurement group_id="O4" value="0.27" lower_limit="0.16" upper_limit="0.45"/>
                    <measurement group_id="O5" value="0.31" lower_limit="0.2" upper_limit="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6A, Pre-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="0.03" upper_limit="0.06"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.03" upper_limit="0.04"/>
                    <measurement group_id="O3" value="0.24" lower_limit="0.17" upper_limit="0.34"/>
                    <measurement group_id="O4" value="0.24" lower_limit="0.15" upper_limit="0.38"/>
                    <measurement group_id="O5" value="0.27" lower_limit="0.18" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6A, Post-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="0.03" upper_limit="0.06"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.03" upper_limit="0.06"/>
                    <measurement group_id="O3" value="0.53" lower_limit="0.35" upper_limit="0.79"/>
                    <measurement group_id="O4" value="0.56" lower_limit="0.36" upper_limit="0.87"/>
                    <measurement group_id="O5" value="0.58" lower_limit="0.37" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19A, Post-Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" lower_limit="0.04" upper_limit="0.12"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.03" upper_limit="0.06"/>
                    <measurement group_id="O3" value="1.08" lower_limit="0.71" upper_limit="1.62"/>
                    <measurement group_id="O4" value="0.97" lower_limit="0.63" upper_limit="1.48"/>
                    <measurement group_id="O5" value="0.93" lower_limit="0.61" upper_limit="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19A, Pre-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" lower_limit="0.04" upper_limit="0.1"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.04" upper_limit="0.06"/>
                    <measurement group_id="O3" value="0.85" lower_limit="0.61" upper_limit="1.17"/>
                    <measurement group_id="O4" value="0.68" lower_limit="0.47" upper_limit="0.98"/>
                    <measurement group_id="O5" value="0.62" lower_limit="0.42" upper_limit="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19A, Post-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" lower_limit="0.05" upper_limit="0.11"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.04" upper_limit="0.07"/>
                    <measurement group_id="O3" value="2.76" lower_limit="1.92" upper_limit="3.96"/>
                    <measurement group_id="O4" value="2.98" lower_limit="2.08" upper_limit="4.26"/>
                    <measurement group_id="O5" value="2.06" lower_limit="1.3" upper_limit="3.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes and Cross-reactive Serotypes</title>
        <description>Seropositivity status, defined as Opsonophagocytic activity against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F and cross-reactive serotypes 6A and 19A ≥ 8.</description>
        <time_frame>One month post-dose 2 (Month 3), prior to the booster dose (Month 6) and one month post-booster (Month 7)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK 2189242A-LD Group</title>
            <description>Subjects received 2 primary vaccination doses of GSK Biologicals’ candidate pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, Low Dose (LD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O2">
            <title>GSK 2189242A-HD Group</title>
            <description>Subjects received 2 primary vaccination doses of GSK Biologicals’ candidate pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, High Dose (HD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O3">
            <title>Synflorix/GSK 2189242A-LD Group</title>
            <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine combined with the pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, Low Dose (LD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O4">
            <title>Synflorix/GSK 2189242A-HD Group</title>
            <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine combined with the pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, High Dose (HD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O5">
            <title>Synflorix Group</title>
            <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
        </group_list>
        <measure>
          <title>Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes and Cross-reactive Serotypes</title>
          <description>Seropositivity status, defined as Opsonophagocytic activity against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F and cross-reactive serotypes 6A and 19A ≥ 8.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OPSONO-1, Post-Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="30"/>
                    <count group_id="O5" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="5.4" lower_limit="3.8" upper_limit="7.8"/>
                    <measurement group_id="O3" value="71.8" lower_limit="40.9" upper_limit="126.1"/>
                    <measurement group_id="O4" value="48.2" lower_limit="26.5" upper_limit="87.6"/>
                    <measurement group_id="O5" value="90" lower_limit="52.9" upper_limit="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-1, Pre-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4.3" lower_limit="3.7" upper_limit="5"/>
                    <measurement group_id="O3" value="23" lower_limit="13.1" upper_limit="40.3"/>
                    <measurement group_id="O4" value="12.4" lower_limit="7.6" upper_limit="20.3"/>
                    <measurement group_id="O5" value="19.3" lower_limit="11.1" upper_limit="33.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-1, Post-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" lower_limit="4" upper_limit="6.9"/>
                    <measurement group_id="O2" value="8.1" lower_limit="4.8" upper_limit="13.7"/>
                    <measurement group_id="O3" value="169.5" lower_limit="96.1" upper_limit="298.8"/>
                    <measurement group_id="O4" value="200" lower_limit="138.2" upper_limit="289.4"/>
                    <measurement group_id="O5" value="206.9" lower_limit="123.1" upper_limit="347.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-4, Post-Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="29"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="3.1" upper_limit="15.6"/>
                    <measurement group_id="O2" value="8.9" lower_limit="4.5" upper_limit="17.6"/>
                    <measurement group_id="O3" value="1260.2" lower_limit="856.1" upper_limit="1855.2"/>
                    <measurement group_id="O4" value="1197.9" lower_limit="784.1" upper_limit="1830.2"/>
                    <measurement group_id="O5" value="1220.4" lower_limit="913.8" upper_limit="1629.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-4, Pre-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" lower_limit="5.6" upper_limit="28.4"/>
                    <measurement group_id="O2" value="16.2" lower_limit="7" upper_limit="37.2"/>
                    <measurement group_id="O3" value="247.9" lower_limit="117.4" upper_limit="523.2"/>
                    <measurement group_id="O4" value="259.9" lower_limit="120.6" upper_limit="560"/>
                    <measurement group_id="O5" value="478.9" lower_limit="309.3" upper_limit="741.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-4, Post-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" lower_limit="6.1" upper_limit="39.5"/>
                    <measurement group_id="O2" value="17.8" lower_limit="7.3" upper_limit="43.4"/>
                    <measurement group_id="O3" value="1206.2" lower_limit="888.9" upper_limit="1636.8"/>
                    <measurement group_id="O4" value="1385" lower_limit="974.5" upper_limit="1968.4"/>
                    <measurement group_id="O5" value="1476" lower_limit="1076" upper_limit="2024.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-5, Post-Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="30"/>
                    <count group_id="O5" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4.7" lower_limit="3.4" upper_limit="6.5"/>
                    <measurement group_id="O3" value="43.8" lower_limit="27.1" upper_limit="70.8"/>
                    <measurement group_id="O4" value="37.3" lower_limit="21.7" upper_limit="64"/>
                    <measurement group_id="O5" value="42" lower_limit="26.6" upper_limit="66.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-5, Pre-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="3.5" upper_limit="5.8"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="12.8" lower_limit="8.2" upper_limit="19.9"/>
                    <measurement group_id="O4" value="14.8" lower_limit="9.6" upper_limit="23"/>
                    <measurement group_id="O5" value="17" lower_limit="10.9" upper_limit="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-5, Post-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="5.1" lower_limit="3.8" upper_limit="6.7"/>
                    <measurement group_id="O3" value="99.3" lower_limit="62.1" upper_limit="158.8"/>
                    <measurement group_id="O4" value="110.4" lower_limit="73.1" upper_limit="166.8"/>
                    <measurement group_id="O5" value="160.7" lower_limit="113" upper_limit="228.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-6B, Post-Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="4.2" upper_limit="53.1"/>
                    <measurement group_id="O2" value="23.4" lower_limit="6.1" upper_limit="90.3"/>
                    <measurement group_id="O3" value="361.9" lower_limit="120" upper_limit="1091.7"/>
                    <measurement group_id="O4" value="527.5" lower_limit="202.6" upper_limit="1372.9"/>
                    <measurement group_id="O5" value="915.3" lower_limit="543.4" upper_limit="1541.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-6B, Pre-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="30"/>
                    <count group_id="O5" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.7" lower_limit="16.2" upper_limit="198.4"/>
                    <measurement group_id="O2" value="61.6" lower_limit="19.2" upper_limit="197.3"/>
                    <measurement group_id="O3" value="213.8" lower_limit="79" upper_limit="578.1"/>
                    <measurement group_id="O4" value="513.1" lower_limit="243.9" upper_limit="1079.6"/>
                    <measurement group_id="O5" value="371.9" lower_limit="172.5" upper_limit="801.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-6B, Post-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1" lower_limit="7.7" upper_limit="88.7"/>
                    <measurement group_id="O2" value="30.8" lower_limit="11.2" upper_limit="84.7"/>
                    <measurement group_id="O3" value="804.6" lower_limit="343.5" upper_limit="1884.9"/>
                    <measurement group_id="O4" value="982.7" lower_limit="527.6" upper_limit="1830.4"/>
                    <measurement group_id="O5" value="1523.1" lower_limit="875.8" upper_limit="2649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-7F, Post-Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="29"/>
                    <count group_id="O5" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="734.6" lower_limit="369.7" upper_limit="1459.6"/>
                    <measurement group_id="O2" value="807.4" lower_limit="445" upper_limit="1465.2"/>
                    <measurement group_id="O3" value="5703.7" lower_limit="4143.6" upper_limit="7851.2"/>
                    <measurement group_id="O4" value="4936.6" lower_limit="3320.7" upper_limit="7338.7"/>
                    <measurement group_id="O5" value="6154.4" lower_limit="4244.4" upper_limit="8923.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-7F, Pre-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="670.4" lower_limit="317.5" upper_limit="1415.6"/>
                    <measurement group_id="O2" value="462.3" lower_limit="187.5" upper_limit="1139.8"/>
                    <measurement group_id="O3" value="2450.1" lower_limit="1637.4" upper_limit="3666.2"/>
                    <measurement group_id="O4" value="2713.5" lower_limit="1836.1" upper_limit="4010.1"/>
                    <measurement group_id="O5" value="3844.5" lower_limit="2725.7" upper_limit="5422.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-7F, Post-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="936.8" lower_limit="510" upper_limit="1720.7"/>
                    <measurement group_id="O2" value="785.5" lower_limit="428" upper_limit="1441.6"/>
                    <measurement group_id="O3" value="4109.3" lower_limit="3086.9" upper_limit="5470.3"/>
                    <measurement group_id="O4" value="5730.4" lower_limit="4262" upper_limit="7704.7"/>
                    <measurement group_id="O5" value="7404.7" lower_limit="5271.1" upper_limit="10401.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-9V, Post-Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="29"/>
                    <count group_id="O5" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5" lower_limit="8.2" upper_limit="85.9"/>
                    <measurement group_id="O2" value="50.1" lower_limit="17.5" upper_limit="143.7"/>
                    <measurement group_id="O3" value="4455" lower_limit="2803.3" upper_limit="7079.9"/>
                    <measurement group_id="O4" value="3542.8" lower_limit="2271.5" upper_limit="5525.5"/>
                    <measurement group_id="O5" value="3947.2" lower_limit="2612.7" upper_limit="5963.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-9V, Pre-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172.4" lower_limit="68.9" upper_limit="431.4"/>
                    <measurement group_id="O2" value="172" lower_limit="57.6" upper_limit="513.2"/>
                    <measurement group_id="O3" value="2126.1" lower_limit="1140.2" upper_limit="3964.4"/>
                    <measurement group_id="O4" value="2622.4" lower_limit="1786.7" upper_limit="3849"/>
                    <measurement group_id="O5" value="3450" lower_limit="2357.5" upper_limit="5048.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-9V, Post-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173.5" lower_limit="59.1" upper_limit="509.8"/>
                    <measurement group_id="O2" value="137.6" lower_limit="51.7" upper_limit="366"/>
                    <measurement group_id="O3" value="4643.1" lower_limit="3418.3" upper_limit="6306.9"/>
                    <measurement group_id="O4" value="5802.4" lower_limit="4453" upper_limit="7560.8"/>
                    <measurement group_id="O5" value="6016.6" lower_limit="4617.2" upper_limit="7840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-14, Post-Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="29"/>
                    <count group_id="O5" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1" lower_limit="6.7" upper_limit="66.8"/>
                    <measurement group_id="O2" value="11.9" lower_limit="4.7" upper_limit="30.4"/>
                    <measurement group_id="O3" value="3324.8" lower_limit="2324.8" upper_limit="4754.8"/>
                    <measurement group_id="O4" value="2580.7" lower_limit="1788.4" upper_limit="3724"/>
                    <measurement group_id="O5" value="2487.6" lower_limit="1703.4" upper_limit="3632.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-14, Pre-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="8.5" upper_limit="51.6"/>
                    <measurement group_id="O2" value="27.9" lower_limit="10.4" upper_limit="75.1"/>
                    <measurement group_id="O3" value="1390.5" lower_limit="615.7" upper_limit="3140.4"/>
                    <measurement group_id="O4" value="1725.8" lower_limit="972.1" upper_limit="3064"/>
                    <measurement group_id="O5" value="1776.6" lower_limit="1009.5" upper_limit="3126.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-14, Post-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3" lower_limit="11.5" upper_limit="90.9"/>
                    <measurement group_id="O2" value="46.7" lower_limit="17" upper_limit="127.8"/>
                    <measurement group_id="O3" value="2911.6" lower_limit="1841.3" upper_limit="4604"/>
                    <measurement group_id="O4" value="3729.8" lower_limit="2693.2" upper_limit="5165.4"/>
                    <measurement group_id="O5" value="3094" lower_limit="2353.3" upper_limit="4068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-18C, Post-Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="7.4" lower_limit="3.7" upper_limit="15.1"/>
                    <measurement group_id="O3" value="1398.3" lower_limit="810.6" upper_limit="2412"/>
                    <measurement group_id="O4" value="2538.4" lower_limit="1787.3" upper_limit="3605"/>
                    <measurement group_id="O5" value="1905.4" lower_limit="1271.4" upper_limit="2855.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-18C, Pre-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="3.4" upper_limit="8.3"/>
                    <measurement group_id="O2" value="5" lower_limit="3.7" upper_limit="6.8"/>
                    <measurement group_id="O3" value="420.1" lower_limit="192.8" upper_limit="915.3"/>
                    <measurement group_id="O4" value="1041" lower_limit="699.6" upper_limit="1548.9"/>
                    <measurement group_id="O5" value="766.4" lower_limit="468.4" upper_limit="1253.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-18C, Post-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="3.3" upper_limit="10.7"/>
                    <measurement group_id="O2" value="8" lower_limit="4.4" upper_limit="14.6"/>
                    <measurement group_id="O3" value="1764.6" lower_limit="1243.6" upper_limit="2503.8"/>
                    <measurement group_id="O4" value="2640.6" lower_limit="2083.3" upper_limit="3346.8"/>
                    <measurement group_id="O5" value="2123.4" lower_limit="1493" upper_limit="3020.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-19F, Pre-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="3.1" upper_limit="8.2"/>
                    <measurement group_id="O2" value="8" lower_limit="4.3" upper_limit="14.7"/>
                    <measurement group_id="O3" value="794.3" lower_limit="476.6" upper_limit="1324"/>
                    <measurement group_id="O4" value="420.7" lower_limit="197.4" upper_limit="896.4"/>
                    <measurement group_id="O5" value="625.4" lower_limit="266.5" upper_limit="1467.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-19F, Post-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" lower_limit="3.5" upper_limit="6.8"/>
                    <measurement group_id="O2" value="4.4" lower_limit="3.7" upper_limit="5.2"/>
                    <measurement group_id="O3" value="173.3" lower_limit="86.1" upper_limit="349"/>
                    <measurement group_id="O4" value="210.1" lower_limit="118.4" upper_limit="373"/>
                    <measurement group_id="O5" value="260.7" lower_limit="138" upper_limit="492.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-19F, Post-Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="3.4" upper_limit="9.1"/>
                    <measurement group_id="O2" value="7.3" lower_limit="4.3" upper_limit="12.6"/>
                    <measurement group_id="O3" value="1248.5" lower_limit="740.4" upper_limit="2105.3"/>
                    <measurement group_id="O4" value="1823.7" lower_limit="1252.9" upper_limit="2654.5"/>
                    <measurement group_id="O5" value="1625.3" lower_limit="931.7" upper_limit="2835.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-23F, Post-Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9" lower_limit="5.1" upper_limit="62.9"/>
                    <measurement group_id="O2" value="107.8" lower_limit="28.1" upper_limit="412.8"/>
                    <measurement group_id="O3" value="1735.5" lower_limit="833.6" upper_limit="3613.3"/>
                    <measurement group_id="O4" value="3621.8" lower_limit="2431.4" upper_limit="5395.2"/>
                    <measurement group_id="O5" value="2502.5" lower_limit="1610.5" upper_limit="3888.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-23F, Pre-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2" lower_limit="7.6" upper_limit="70.3"/>
                    <measurement group_id="O2" value="136.3" lower_limit="36.1" upper_limit="514.6"/>
                    <measurement group_id="O3" value="989.7" lower_limit="419.2" upper_limit="2336.8"/>
                    <measurement group_id="O4" value="1635.9" lower_limit="691.7" upper_limit="3868.8"/>
                    <measurement group_id="O5" value="897.4" lower_limit="381.6" upper_limit="2110.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-23F, Post-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.6" lower_limit="17.3" upper_limit="271.2"/>
                    <measurement group_id="O2" value="106.7" lower_limit="28.5" upper_limit="399.4"/>
                    <measurement group_id="O3" value="3598.5" lower_limit="2422.2" upper_limit="5345.9"/>
                    <measurement group_id="O4" value="6108" lower_limit="4335.9" upper_limit="8604.5"/>
                    <measurement group_id="O5" value="5296.1" lower_limit="3857.9" upper_limit="7270.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-6A, Post-Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" lower_limit="3.5" upper_limit="24.7"/>
                    <measurement group_id="O2" value="5.7" lower_limit="3.4" upper_limit="9.5"/>
                    <measurement group_id="O3" value="225.3" lower_limit="83.3" upper_limit="608.8"/>
                    <measurement group_id="O4" value="186.2" lower_limit="55.3" upper_limit="627.2"/>
                    <measurement group_id="O5" value="364.5" lower_limit="158.7" upper_limit="837.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-6A, Pre-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" lower_limit="7.6" upper_limit="44.5"/>
                    <measurement group_id="O2" value="9.4" lower_limit="4.5" upper_limit="19.5"/>
                    <measurement group_id="O3" value="58.9" lower_limit="21.6" upper_limit="160.3"/>
                    <measurement group_id="O4" value="99.4" lower_limit="39.9" upper_limit="247.8"/>
                    <measurement group_id="O5" value="221.7" lower_limit="93.8" upper_limit="524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-6A, Post-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" lower_limit="4.7" upper_limit="29.5"/>
                    <measurement group_id="O2" value="17.3" lower_limit="7.9" upper_limit="37.9"/>
                    <measurement group_id="O3" value="308" lower_limit="141" upper_limit="672.9"/>
                    <measurement group_id="O4" value="348.2" lower_limit="154.9" upper_limit="782.5"/>
                    <measurement group_id="O5" value="554.3" lower_limit="248.3" upper_limit="1237.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-19A, Post-Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" lower_limit="3.4" upper_limit="9.9"/>
                    <measurement group_id="O2" value="4.6" lower_limit="3.7" upper_limit="5.6"/>
                    <measurement group_id="O3" value="246" lower_limit="109.7" upper_limit="551.7"/>
                    <measurement group_id="O4" value="363.2" lower_limit="202.1" upper_limit="652.8"/>
                    <measurement group_id="O5" value="349.9" lower_limit="177.1" upper_limit="691.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-19A, Pre-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="4" upper_limit="9.1"/>
                    <measurement group_id="O2" value="4.5" lower_limit="3.8" upper_limit="5.3"/>
                    <measurement group_id="O3" value="56.7" lower_limit="25.2" upper_limit="127.9"/>
                    <measurement group_id="O4" value="76.4" lower_limit="36.3" upper_limit="160.7"/>
                    <measurement group_id="O5" value="87.8" lower_limit="40.6" upper_limit="189.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPSONO-19A, Post-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="4.3" upper_limit="10.3"/>
                    <measurement group_id="O2" value="6.3" lower_limit="4.4" upper_limit="9.1"/>
                    <measurement group_id="O3" value="746.3" lower_limit="407.8" upper_limit="1365.6"/>
                    <measurement group_id="O4" value="989.3" lower_limit="652.5" upper_limit="1500"/>
                    <measurement group_id="O5" value="725.9" lower_limit="367.8" upper_limit="1432.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations to Protein D (Anti-PD)</title>
        <description>Seropositivity status, defined as anti-PD antibody concentrations ≥ 112 Luminex Units per milliliter (LU/mL).</description>
        <time_frame>One month post-dose 2 (Month 3), prior to the booster dose (Month 6) and one month post-booster (Month 7)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK 2189242A-LD Group</title>
            <description>Subjects received 2 primary vaccination doses of GSK Biologicals’ candidate pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, Low Dose (LD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O2">
            <title>GSK 2189242A-HD Group</title>
            <description>Subjects received 2 primary vaccination doses of GSK Biologicals’ candidate pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, High Dose (HD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O3">
            <title>Synflorix/GSK 2189242A-LD Group</title>
            <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine combined with the pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, Low Dose (LD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O4">
            <title>Synflorix/GSK 2189242A-HD Group</title>
            <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine combined with the pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, High Dose (HD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O5">
            <title>Synflorix Group</title>
            <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations to Protein D (Anti-PD)</title>
          <description>Seropositivity status, defined as anti-PD antibody concentrations ≥ 112 Luminex Units per milliliter (LU/mL).</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
          <units>LU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PD, Post-Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9" lower_limit="71.1" upper_limit="116.3"/>
                    <measurement group_id="O2" value="100.4" lower_limit="76.3" upper_limit="132.1"/>
                    <measurement group_id="O3" value="1105.4" lower_limit="833.7" upper_limit="1465.7"/>
                    <measurement group_id="O4" value="600.2" lower_limit="426.5" upper_limit="844.7"/>
                    <measurement group_id="O5" value="860" lower_limit="659.2" upper_limit="1121.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PD, Pre-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.1" lower_limit="71.8" upper_limit="110.7"/>
                    <measurement group_id="O2" value="118.2" lower_limit="89.6" upper_limit="155.9"/>
                    <measurement group_id="O3" value="734.6" lower_limit="523.9" upper_limit="1030.1"/>
                    <measurement group_id="O4" value="463" lower_limit="330.2" upper_limit="649.3"/>
                    <measurement group_id="O5" value="691.8" lower_limit="527.6" upper_limit="907.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PD, Post-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.9" lower_limit="78" upper_limit="122.9"/>
                    <measurement group_id="O2" value="130.6" lower_limit="93.1" upper_limit="183.3"/>
                    <measurement group_id="O3" value="1882.6" lower_limit="1407.4" upper_limit="2518.1"/>
                    <measurement group_id="O4" value="1474.6" lower_limit="1103.7" upper_limit="1970.3"/>
                    <measurement group_id="O5" value="1963.8" lower_limit="1560.1" upper_limit="2472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Level of Anti-dPly Antibodies Inhibiting Ply Haemolysis Activity</title>
        <description>Inhibition of haemolysis activity of pneumolysin (Ply) by anti-dPly antibodies was measured in vitro by mean of a haemolytic assay. The haemolysis activity could be followed by measuring the level of haemoglobin released. Anti-dPly titers (for inhibition of haemolytic activity) ≥ 140.</description>
        <time_frame>One month post-dose 2 (Month 3), prior to the booster dose (Month 6) and one month post-booster (Month 7)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK 2189242A-LD Group</title>
            <description>Subjects received 2 primary vaccination doses of GSK Biologicals’ candidate pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, Low Dose (LD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O2">
            <title>GSK 2189242A-HD Group</title>
            <description>Subjects received 2 primary vaccination doses of GSK Biologicals’ candidate pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, High Dose (HD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O3">
            <title>Synflorix/GSK 2189242A-LD Group</title>
            <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine combined with the pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, Low Dose (LD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O4">
            <title>Synflorix/GSK 2189242A-HD Group</title>
            <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine combined with the pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, High Dose (HD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
          <group group_id="O5">
            <title>Synflorix Group</title>
            <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
          </group>
        </group_list>
        <measure>
          <title>Level of Anti-dPly Antibodies Inhibiting Ply Haemolysis Activity</title>
          <description>Inhibition of haemolysis activity of pneumolysin (Ply) by anti-dPly antibodies was measured in vitro by mean of a haemolytic assay. The haemolysis activity could be followed by measuring the level of haemoglobin released. Anti-dPly titers (for inhibition of haemolytic activity) ≥ 140.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Hem-dPly, Post-Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3080" lower_limit="2555.3" upper_limit="3712.5"/>
                    <measurement group_id="O2" value="2988.7" lower_limit="2410.1" upper_limit="3706.2"/>
                    <measurement group_id="O3" value="1278.9" lower_limit="1048.2" upper_limit="1560.3"/>
                    <measurement group_id="O4" value="1814" lower_limit="1495.3" upper_limit="2200.8"/>
                    <measurement group_id="O5" value="913.2" lower_limit="699.1" upper_limit="1192.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Hem-dPly, Pre-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2441.1" lower_limit="1867.1" upper_limit="3191.7"/>
                    <measurement group_id="O2" value="2193.7" lower_limit="1737.3" upper_limit="2770"/>
                    <measurement group_id="O3" value="1141.5" lower_limit="950.6" upper_limit="1370.6"/>
                    <measurement group_id="O4" value="1344.2" lower_limit="1087.6" upper_limit="1661.3"/>
                    <measurement group_id="O5" value="995.9" lower_limit="788.3" upper_limit="1258.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Hem-dPly, Post-booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4332.4" lower_limit="3327.6" upper_limit="5640.4"/>
                    <measurement group_id="O2" value="5931.9" lower_limit="4744.5" upper_limit="7416.4"/>
                    <measurement group_id="O3" value="1346.2" lower_limit="1068.2" upper_limit="1696.5"/>
                    <measurement group_id="O4" value="2388.3" lower_limit="1830.6" upper_limit="3115.9"/>
                    <measurement group_id="O5" value="818.6" lower_limit="662.5" upper_limit="1011.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited local and general symptoms: during the 7-day (Days 0-6) post-primary and post-booster vaccination period; Unsolicited AEs: during the 31-day (Days 0-30) post-primary and post-booster vaccination period; SAEs: during the whole study period (from Day 0 up to Month 7).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GSK 2189242A-LD Group</title>
          <description>Subjects received 2 primary vaccination doses of GSK Biologicals’ candidate pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, Low Dose (LD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
        </group>
        <group group_id="E2">
          <title>GSK 2189242A-HD Group</title>
          <description>Subjects received 2 primary vaccination doses of GSK Biologicals’ candidate pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, High Dose (HD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
        </group>
        <group group_id="E3">
          <title>Synflorix/GSK 2189242A-LD Group</title>
          <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine combined with the pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, Low Dose (LD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
        </group>
        <group group_id="E4">
          <title>Synflorix/GSK 2189242A-HD Group</title>
          <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine combined with the pneumococcal protein vaccine (GSK 2189242A) containing the pneumococcal proteins dPly and PhtD, High Dose (HD) vaccine formulation, at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
        </group>
        <group group_id="E5">
          <title>Synflorix Group</title>
          <description>Subjects received 2 primary vaccination doses of Synflorix™ vaccine at Month 0 and Month 2 and a booster dose at Month 6. The vaccine was administered intramuscularly, into the deltoid muscle or into the anterolateral thigh (if the deltoid muscle size was not adequate).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pharyngo-tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Accidental exposure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Open wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adenoidal hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="35" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain Primary</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Redness Primary</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Swelling Primary</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pain Booster</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Redness Booster</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Swelling Booster</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Drowsiness Primary</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="35" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Irritability Primary</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="35" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Loss of appetite Primary</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Temperature/Rectally Primary</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Drowsiness Booster</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Irritability Booster</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Loss of appetite Booster</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Temperature/Rectally Booster</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis Primary</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis Booster</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Rhinitis Primary</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Rhinitis Booster</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

